Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Minority Interest (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Minority Interest for 6 consecutive years, with $96000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Minority Interest fell 42.51% year-over-year to $96000.0, compared with a TTM value of $96000.0 through Sep 2025, down 42.51%, and an annual FY2024 reading of $106000.0, down 49.76% over the prior year.
  • Minority Interest was $96000.0 for Q3 2025 at Barinthus Biotherapeutics, down from $104000.0 in the prior quarter.
  • Across five years, Minority Interest topped out at $33.7 million in Q1 2021 and bottomed at $96000.0 in Q3 2025.
  • Average Minority Interest over 5 years is $2.0 million, with a median of $253000.0 recorded in 2023.
  • The sharpest move saw Minority Interest grew 11.76% in 2021, then plummeted 98.81% in 2022.
  • Year by year, Minority Interest stood at $437000.0 in 2021, then plummeted by 30.21% to $305000.0 in 2022, then crashed by 30.82% to $211000.0 in 2023, then plummeted by 49.76% to $106000.0 in 2024, then decreased by 9.43% to $96000.0 in 2025.
  • Business Quant data shows Minority Interest for BRNS at $96000.0 in Q3 2025, $104000.0 in Q2 2025, and $99000.0 in Q1 2025.